Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Day One Biopharmaceuticals Inc
(NQ:
DAWN
)
15.65
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1
Open
15.65
Bid (Size)
12.00 (4)
Ask (Size)
19.47 (1)
Prev. Close
15.65
Today's Range
15.65 - 15.65
52wk Range
9.670 - 18.07
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
June 22, 2024
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting...
Via
Talk Markets
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
June 18, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+7.78%
+7.78%
1 Month
+30.09%
+30.09%
3 Month
+5.39%
+5.39%
6 Month
+13.32%
+13.32%
1 Year
+35.62%
+35.62%
More News
Read More
Day One Announces Sale of Priority Review Voucher for $108 Million
May 30, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
May 06, 2024
Via
InvestorPlace
Analyst Ratings for Day One Biopharmaceutical
November 07, 2023
Via
Benzinga
The Latest Analyst Ratings for Day One Biopharmaceutical
September 12, 2023
Via
Benzinga
Where Day One Biopharmaceutical Stands With Analysts
August 08, 2023
Via
Benzinga
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
May 06, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
April 23, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
February 26, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
January 17, 2024
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
November 17, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
November 06, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Dow Up Over 340 Points As Stocks Snap Back
October 30, 2023
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 30, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 26, 2023
Via
Benzinga
$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
October 23, 2023
Via
Benzinga
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
August 16, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
August 07, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
$3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying
June 13, 2023
Via
Benzinga
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
June 12, 2023
From
Day One Biopharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.